RhinoCytes

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameRhinoCytes
Drug Alias NameRhinoCyte technologyRhinoCyteautologous stem cell therapy (RhinoCyte/University of Louisville)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Neurogenic potential stem cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Olfactory stem cell therapy
Mechanisms of ActionInsulin release stimulants
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 1Spinal Cord InjuriesAmyotrophic Lateral Sclerosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Louisville
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRhinoCyte IncUniversity Of Louisville
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 1Spinal Cord InjuriesAmyotrophic Lateral Sclerosis +[5] 

Other Information

ATC CodeN/A
Related LinksN/A